Page last updated: 2024-11-04

ifenprodil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Ifenprodil is a non-competitive NMDA receptor antagonist that has been studied for its potential therapeutic effects in neurological disorders such as stroke, Alzheimer's disease, and Parkinson's disease. Ifenprodil is known to selectively block the GluN2B subunit of the NMDA receptor. Its synthesis involves several steps, including a condensation reaction of a substituted benzophenone with a substituted aniline. Its importance lies in its ability to modulate glutamate neurotransmission, a critical process involved in learning, memory, and synaptic plasticity. It is studied for its potential to protect against neuronal damage and promote neuroprotection in various neurological conditions. However, further research is necessary to fully understand its safety and efficacy in humans. '

ifenprodil: NMDA receptor antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3689
CHEMBL ID305187
CHEMBL ID_104385
CHEBI ID93829
SCHEMBL ID34010
MeSH IDM0056488

Synonyms (80)

Synonym
BRD-A24191444-045-03-1
2-(4-benzylpiperidino)-1-(4-hydroxyphenyl)-1-propanol hemitartrate
4-[2-(4-benzyl-1-piperidyl)-1-hydroxy-propyl]phenol; (2r,3r)-2,3-dihydroxybutanedioic acid
PDSP2_000646
PDSP1_000654
1-piperidineethanol, alpha-(4-hydroxyphenyl)-beta-methyl-4-(phenylmethyl)-
1-piperidineethanol, 4-benzyl-alpha-(p-hydroxyphenyl)-beta-methyl-
creocral
4-benzyl-alpha-(p-hydroxyphenyl)-beta-methyl-1-piperidineethanol
ifenprodil [inn:dcf]
rc 61-91
alpha-(4-hydroxyphenyl)-beta-methyl-4-(phenylmethyl)-1-piperidine ethanol
einecs 245-491-4
2-(4-benzylpiperidino)-1-(4-hydroxyphenyl)propanol
dilvax
ifenprodilum [inn-latin]
ifenprodil
NCGC00024643-04
NCGC00024643-03
NCGC00024643-02
NCGC00024643-05
23210-56-2
HMS2089G05
NCGC00024643-06
bdbm50083351
chembl305187 ,
chembl_104385
4-(2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl)phenol
(+/-)-[2-(4-benzylpiperidino)-1-(4-hydroxyphenyl)-1-propanol]
L005364
ifenprodil (inn)
D08064
4-[2-(4-benzylpiperidin-1-yl)-1-hydroxypropyl]phenol
NCGC00024643-07
np-120
rc-61-91
A816623
dtxsid2045656 ,
dtxcid0025656
tox21_110915
cas-23210-56-2
CCG-204747
r8oe3p6o5s ,
ifenprodilum
unii-r8oe3p6o5s
FT-0601591
AKOS015895174
(plusmn)-ifenprodil
gtpl5472
SCHEMBL34010
tox21_110915_1
NCGC00024643-10
ifenprodil [mi]
ifenprodil [inn]
4-benzyl-.alpha.-(p-hydroxyphenyl)-.beta.-methyl-1-piperidineethanol
ifenprodil [who-dd]
UYNVMODNBIQBMV-UHFFFAOYSA-N
ifenprodil (tartrate)
DB08954
4-[1-hydroxy-2-[4-(phenylmethyl)-1-piperidinyl]propyl]phenol
CHEBI:93829
1-piperidineethanol, .alpha.-(4-hydroxyphenyl)-.beta.-methyl-4-(phenylmethyl)-
J-015034
sr-01000075169
SR-01000075169-1
SR-01000075169-3
SR-01000075169-11
SBI-0050640.P002
MRF-0000097
NCGC00024643-12
Q5991156
136172-79-7
4605A
SDCCGSBI-0050640.P003
NCGC00024643-20
(+/-)-ifenprodil;rc 61-91
A918608
()-ifenprodil;rc 61-91
YAA21058
EN300-18166867

Research Excerpts

Overview

Ifenprodil tartrate is a neuroprotective agent that binds to the GluN2B subunit of the NMDA receptor. It is a blocker of G protein-activated inwardly rectifying potassium channels, which play a key role in the mechanism of action of addictive substances.

ExcerptReferenceRelevance
"Ifenprodil is a blocker of G protein-activated inwardly rectifying potassium channels, which play a key role in the mechanism of action of addictive substances."( Ifenprodil for the treatment of methamphetamine use disorder: An exploratory, randomized, double-blind, placebo-controlled trial.
Ban, E; Funada, D; Hirakawa, S; Ikeda, K; Kawashima, T; Kikuchi, M; Kotajima-Murakami, H; Maruo, K; Matsumoto, T; Ogai, Y; Oi, H; Sasaki, T; Tachimori, H; Takano, A; Tanibuchi, Y; Tomo, Y, 2022
)
2.89
"Ifenprodil tartrate is a neuroprotective agent that binds to the GluN2B subunit of the NMDA receptor."( Ifenprodil tartrate treatment of adolescents with post-traumatic stress disorder: A double-blind, placebo-controlled trial.
Hanaoka, H; Hashimoto, K; Hashimoto, T; Hosoda, Y; Iyo, M; Kanahara, N; Kawasaki, Y; Niitsu, T; Oda, Y; Ozawa, Y; Sasaki, T; Shiina, A; Shiko, Y; Sugawara, T; Suzuki, T, 2022
)
2.89
"Ifenprodil is a blocker of G protein-activated inwardly rectifying potassium channels that play a key role in the mechanism of action of addictive substances."( Study of effects of ifenprodil in patients with methamphetamine dependence: Protocol for an exploratory, randomized, double-blind, placebo-controlled trial.
Funada, D; Ikeda, K; Kotajima-Murakami, H; Maruo, K; Matsumoto, T; Murakami, M; Ogai, Y; Sasaki, T; Tachimori, H; Takano, A; Tanibuchi, Y; Tsukamoto, S, 2019
)
1.56
"Ifenprodil is an antagonist selective for N-methyl D-aspartate receptor 2B (NR2B) subunits."( Ifenprodil induced antinociception and decreased the expression of NR2B subunits in the dorsal horn after chronic dorsal root ganglia compression in rats.
Gu, XP; Ma, ZL; Shi, CX; Zhang, W; Zhu, W, 2009
)
2.52
"Ifenprodil is a novel NMDA receptor antagonist that selectively inhibits receptors containing the NR2B subunit. "( Influence of NR2B-selective NMDA antagonist on lindane-induced seizures in rats.
Djurić, D; Hrncić, D; Rasić-Marković, A; Stanojlović, O; Susić, V, 2009
)
1.8
"Ifenprodil seems to be a potent anti-inflammatory substance for astrocytes which have been pre-activated by inflammatory stimuli."( Ifenprodil restores GDNF-evoked Ca(2+) signalling and Na(+)/K(+) -ATPase expression in inflammation-pretreated astrocytes.
Biber, B; Björklund, U; Hansson, E; Lundborg, C; Westerlund, A, 2011
)
2.53
"Ifenprodil is a selective blocker of NMDA receptors that are heterodimers composed of GluN1/GluN2B subunits. "( Ifenprodil reduces excitatory synaptic transmission by blocking presynaptic P/Q type calcium channels.
Delaney, AJ; Power, JM; Sah, P, 2012
)
3.26
"Ifenprodil is a well tolerated NMDA receptor inhibitor; it is selective for GluN2B-containing receptors and has neuroprotective effects."( Ifenprodil effects on GluN2B-containing glutamate receptors.
Amico-Ruvio, SA; Myers, JM; Paganelli, MA; Popescu, GK, 2012
)
2.54
"Ifenprodil is an allosteric inhibitor of GluN1/GluN2B N-methyl-D-aspartate receptors. "( Effect of ifenprodil on GluN1/GluN2B N-methyl-D-aspartate receptor gating.
Bhatt, JM; Dravid, SM; Prakash, A; Suryavanshi, PS, 2013
)
2.23
"Ifenprodil is a noncompetitive antagonist of NMDA receptors highly selective for the NMDA receptor 2B (NR2B) subunit. "( Mapping the binding site of the neuroprotectant ifenprodil on NMDA receptors.
Neyton, J; Paoletti, P; Perin-Dureau, F; Rachline, J, 2002
)
2.01
"Ifenprodil, which is a clinically used cerebral vasodilator, interacts with several receptors, such as alpha1 adrenergic, N-methyl-D-aspartate, serotonin and sigma receptors."( Inhibition of G protein-activated inwardly rectifying K+ channels by ifenprodil.
Ikeda, K; Kobayashi, T; Washiyama, K, 2006
)
1.29
"Ifenprodil is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist which prefers NR2B-containing NMDA receptors to NR2A-containing NMDA receptors. "( Effects of ifenprodil on the discriminative stimulus effects of cocaine in rhesus monkeys.
Fujiwara, A; Hironaka, N; Iino, M; Sasaki, M; Wakasa, Y; Yanagita, T, 2007
)
2.17
"Ifenprodil is an atypical noncompetitive modulator of the N-methyl-D-aspartate (NMDA) receptor (NR) which demonstrates a 140-fold preference for NR2B over NR2A subunits, although the molecular basis for this subunit specificity is unknown. "( Interactions between ifenprodil and the NR2B subunit of the N-methyl-D-aspartate receptor.
Gallagher, MJ; Huang, H; Lynch, DR; Pritchett, DB, 1996
)
2.06
"1. Ifenprodil is a selective, atypical non-competitive antagonist of NMDA receptors that contain the NR2B subunit with an undefined mechanism of action. "( A novel mechanism of activity-dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurones.
Kemp, JA; Kew, JN; Trube, G, 1996
)
1.14
"Ifenprodil is an atypical N-methyl-D-aspartate (NMDA) receptor antagonist that selectively blocks receptors containing the NR2B subunit. "( Influence of extracellular pH on inhibition by ifenprodil at N-methyl-D-aspartate receptors in Xenopus oocytes.
Pahk, AJ; Williams, K, 1997
)
2
"Ifenprodil is a novel N-methyl-D-aspartate (NMDA) receptor antagonist that selectively inhibits receptors containing the NR2B subunit. "( Ifenprodil, a novel NMDA receptor antagonist: site and mechanism of action.
Williams, K, 2001
)
3.2

Effects

Ifenprodil has a high affinity to the GluN2B subunit but a poor selectivity for the NMDA receptor. Its mechanism of action may involve an increase in proton inhibition of NMDA receptors.

Ifenprodil tartrate has long been employed as a cerebral vasodilator with alpha and N-methyl-D-aspartate (NMDA) receptor antagonistic activities. It has a high affinity to the GluN2B subunit but a poor selectivity for the NMDA receptor.

ExcerptReferenceRelevance
"Ifenprodil itself has a high affinity to the GluN2B subunit but a poor selectivity for the NMDA receptor."( Metabolism studies of ifenprodil, a potent GluN2B receptor antagonist.
Begrow, F; Falck, E; Verspohl, E; Wünsch, B, 2014
)
1.44
"Ifenprodil has an unusual form of activity-dependence and its mechanism of action may involve an increase in proton inhibition of NMDA receptors."( Ifenprodil, a novel NMDA receptor antagonist: site and mechanism of action.
Williams, K, 2001
)
2.47
"Ifenprodil itself has a high affinity to the GluN2B subunit but a poor selectivity for the NMDA receptor."( Metabolism studies of ifenprodil, a potent GluN2B receptor antagonist.
Begrow, F; Falck, E; Verspohl, E; Wünsch, B, 2014
)
1.44
"Ifenprodil has been widely used as an antagonist selective for NMDA receptors containing the NR2B subunit. "( Enhancement of NMDA-induced current by the putative NR2B selective antagonist ifenprodil.
Bunney, BS; Shi, WX; Zhang, XX, 2000
)
1.98
"Ifenprodil tartrate has long been employed as a cerebral vasodilator with alpha and N-methyl-D-aspartate (NMDA) receptor antagonistic activities. "( Effect of ifenprodil on ocular tissue circulation in rabbits.
Araie, M; Matsubara, M; Muta, K; Tamaki, Y, 2000
)
2.15
"Ifenprodil has an unusual form of activity-dependence and its mechanism of action may involve an increase in proton inhibition of NMDA receptors."( Ifenprodil, a novel NMDA receptor antagonist: site and mechanism of action.
Williams, K, 2001
)
2.47

Actions

ExcerptReferenceRelevance
"Ifenprodil is known to inhibit channel opening of NMDA receptors containing the NR2B subunit. "( Dynamic modulation of NMDA-induced responses by ifenprodil in rat prefrontal cortex.
Shi, WX; Zhang, XX, 2001
)
2.01

Treatment

Ifenprodil treatment for both doses showed anti-allodynic and anti-nociceptive effects with lower expression of phosphorylated and total spinal NR2B. Treatment altered aspects of wrestling, social investigatory behaviors, and ultrasonic vocalizations in rats exposed to ethanol during development.

ExcerptReferenceRelevance
"Ifenprodil treatment for both doses showed anti-allodynic and anti-nociceptive effects with lower expression of phosphorylated and total spinal NR2B."( Increased Nociceptive Responses in Streptozotocin-Induced Diabetic Rats and the Related Expression of Spinal NR2B Subunit of
Abd Aziz, CB; Haris, K; Ismail, CAN; Long, I; Suppian, R, 2019
)
1.24
"Ifenprodil treatment altered aspects of wrestling, social investigatory behaviors, and ultrasonic vocalizations in rats exposed to ethanol during development that were not observed in control animals."( Ifenprodil infusion in agranular insular cortex alters social behavior and vocalizations in rats exposed to moderate levels of ethanol during prenatal development.
Barto, D; Bird, CW; Davies, S; Donaldson, T; Hamilton, DA; Magcalas, CM; Rodriguez, CI; Savage, DD, 2017
)
2.62
"Ifenprodil treatment had no effect on either measure."( Differential role of N-methyl-D-aspartate receptor subunits 2A and 2B in mediating phencyclidine-induced perinatal neuronal apoptosis and behavioral deficits.
Anastasio, NC; Johnson, KM; O'Connor, ZR; Xia, Y, 2009
)
1.07
"Ifenprodil treatment also attenuated brain edema formation in the dense ischemic region, compared with saline treatment (1.035 +/- 0.002 versus 1.028 +/- 0.002, P < 0.05)."( Protective effects of ifenprodil on ischemic injury size, blood-brain barrier breakdown, and edema formation in focal cerebral ischemia.
Başkaya, MK; Dempsey, RJ; Donaldson, D; Prasad, MR; Rao, AM, 1997
)
1.33
"Ifenprodil treatment significantly reduced brain edema (82.5 +/- 0.4% vs."( Effects of ifenprodil, a polyamine site NMDA receptor antagonist, on reperfusion injury after transient focal cerebral ischemia.
Başkaya, MK; Dempsey, RJ; Doğan, A; Donaldson, D; Rao, AM; Rao, VL; Rastl, J, 1997
)
1.41
"Ifenprodil treatment reduced injury volume significantly (14.9 +/- 8.1 mm3 versus 24.4 +/- 6.7 mm3, P < 0.05)."( Attenuation of brain edema, blood-brain barrier breakdown, and injury volume by ifenprodil, a polyamine-site N-methyl-D-aspartate receptor antagonist, after experimental traumatic brain injury in rats.
Başkaya, MK; Dempsey, RJ; Doğan, A, 2000
)
1.26
"Pretreatment with ifenprodil that is one of the GIRK channel blockers suppressed addictive substance-induced behaviors in animals."( [Clinical study of GIRK channel inhibitors as candidate medicines for drug dependence].
Ikeda, K; Kotajima-Murakami, H, 2020
)
0.88
"Treatment with ifenprodil, an NR2B subunit-specific NMDA receptor antagonist, without prior injury induction, also increased the number of BrdU-positive cells within the DG and posterior periventricle, indicating that ifenprodil itself could modulate the rate of proliferation."( Effect of the N-methyl-D-aspartate NR2B subunit antagonist ifenprodil on precursor cell proliferation in the hippocampus.
Bunk, EC; Kirby, BP; König, HG; Prehn, JH, 2014
)
0.99
"Pretreatment with ifenprodil resulted in an anticonvulsant effect in 15-day-old rats only, on the contrary, proconvulsant action was found in 18- and 25-day-old animals (decrease of thresholds especially for transition into the second, limbic type of ADs and increase in duration of ADs)."( Age and activation determines the anticonvulsant effect of ifenprodil in rats.
Mareš, P, 2014
)
0.97
"Pretreatment with ifenprodil (1 or 2 mg/kg, i.v.) blocked the cocaine-appropriate response when low doses of cocaine were used."( Effects of ifenprodil on the discriminative stimulus effects of cocaine in rhesus monkeys.
Fujiwara, A; Hironaka, N; Iino, M; Sasaki, M; Wakasa, Y; Yanagita, T, 2007
)
1.05
"Pretreatment with ifenprodil (5-20 mg/kg, i.p.) suppressed the place preference produced by morphine in a dose-dependent manner."( Effects of the non-competitive NMDA receptor antagonist ifenprodil on the morphine-induced place preference in mice.
Kato, H; Misawa, M; Suzuki, H; Suzuki, T; Tsuda, M, 1999
)
0.87
"Pretreatment with ifenprodil or flunarizine, 1 mg/kg i.v., 5 min prior to ischemia prevented the post-ischemic decrease in baroreflex sensitivity."( Selective dysfunction of the vagal component of the baroreflex following cerebral ischemia: protection by ifenprodil and flunarizine.
Kato, H; Kurihara, J; Oda, N; Sahara, T; Tomita, H, 1990
)
0.82

Toxicity

ExcerptReferenceRelevance
" Putrescine was moderately toxic but only at 500 microM concentration."( Neurotoxicity of polyamines and pharmacological neuroprotection in cultures of rat cerebellar granule cells.
Ciani, E; Contestabile, A; Dall'Olio, R; Gandolfi, O; Sparapani, M, 1997
)
0.3
" Moreover, NMDAR involvement causes the fatal activation of calpain, which, in turn, degrades tau protein into a 17-kDa peptide and possibly other highly toxic N-terminal peptides."( NMDA receptor mediates tau-induced neurotoxicity by calpain and ERK/MAPK activation.
Amadoro, G; Calissano, P; Canu, N; Cestari, V; Ciotti, MT; Costanzi, M, 2006
)
0.33

Pharmacokinetics

ExcerptReferenceRelevance
" Herein, pharmacokinetic properties regarding lipophilicity, plasma protein binding (PPB) and metabolism are analyzed."( Pharmacokinetic properties of enantiomerically pure GluN2B selective NMDA receptor antagonists with 3-benzazepine scaffold.
Ametamey, SM; Börgel, F; Galla, F; Lehmkuhl, K; Schepmann, D; Wünsch, B, 2019
)
0.51

Bioavailability

ExcerptReferenceRelevance
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."( Highly predictive and interpretable models for PAMPA permeability.
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017
)
0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"Although N-methyl-d-aspartate receptor antagonists are hopeful therapeutic agents against cerebral ischemia/reperfusion (I/R) injury, effective approaches are needed to allow such agents to pass through the blood-brain barrier, thus increasing bioavailability of the antagonists to realize secure treatment."( Suppression of Cerebral Ischemia/Reperfusion Injury by Efficient Release of Encapsulated Ifenprodil From Liposomes Under Weakly Acidic pH Conditions.
Agato, Y; Asai, T; Fukuta, T; Ishii, T; Kikuchi, T; Koide, H; Oku, N; Shimizu, K; Yanagida, Y, 2019
)
0.74
" Additionally, an ∼85% correlation was obtained between PAMPA pH 5 permeability and in vivo oral bioavailability in mice and rats."( Using in vitro ADME data for lead compound selection: An emphasis on PAMPA pH 5 permeability and oral bioavailability.
Itkin, M; Kabir, M; Mathé, EA; Nguyễn, ÐT; Padilha, EC; Shah, P; Shinn, P; Siramshetty, V; Wang, AQ; Williams, J; Xu, X; Yu, KR; Zhao, T, 2022
)
0.72

Dosage Studied

Ifenprodil tartrate attenuated the NMDA-induced increase in medium GABA at all ages tested with an Imax of 10 microM. The dose-response curve was shifted to the left by pre-incubation in calcium hopantenate.

ExcerptRelevanceReference
" In dose-response studies, ifenprodil attenuated the NMDA-induced increase in medium GABA at all ages tested with an Imax of 10 microM."( Developmental differences in antagonism of NMDA toxicity by the polyamine site antagonist ifenprodil.
Nicklas, WJ; Zeevalk, GD, 1992
)
0.8
" The dose-response curve of ifenprodil tartrate was shifted to the left by pre-incubation in calcium hopantenate."( A possible mechanism on the potentiating vascular effect of coadministration of ifenprodil tartrate and calcium hopantenate: a study in the internal carotid artery.
Honda, H; Irino, O; Iwata, T; Izumisawa, M; Matsuda, H; Shibuya, T; Shimura, H; Tsuji, H; Watanabe, Y, 1988
)
0.8
" The dose-response relations for extracellular Mg2+ blockade of INMDA indicated a high affinity binding of Mg2+ to NMDA receptors at membrane potentials more negative than -60 mV, independent of postnatal age."( Early postnatal switch in magnesium sensitivity of NMDA receptors in rat CA1 pyramidal cells.
Kirson, ED; Konnerth, A; Schirra, C; Yaari, Y, 1999
)
0.3
" Compound 11a also potentiated the effects of L-DOPA in a rat model of Parkinson's disease (the 6-hydroxydopamine-lesioned rat), dosed at 30 mg/kg orally."( Subtype-selective N-methyl-D-aspartate receptor antagonists: benzimidazalone and hydantoin as phenol replacements.
Meltzer, LT; Schelkun, RM; Serpa, K; Whittemore, ER; Wise, LD; Woodward, RM; Yuen, PW, 2000
)
0.31
" Ifenprodil dose-response curves for all receptors were biphasic."( Electrophysiological analysis of NMDA receptor subunit changes in the aging mouse cortex.
Kuehl-Kovarik, MC; Magnusson, KR; Partin, KM; Premkumar, LS, 2000
)
1.22
"3 nM for this subtype (compared to NR1(A)/2A: 35 microM and NR1(A)/2C>100 microM) and was active in rat at a relatively low dosage (10mg/kg po)."( Synthesis, radiosynthesis and in vivo evaluation of 5-[3-(4-benzylpiperidin-1-yl)prop-1-ynyl]-1,3-dihydrobenzoimidazol-2-[(11)C]one, as a potent NR(1A)/2B subtype selective NMDA PET radiotracer.
Besret, L; Bottlaender, M; Bramoullé, Y; Coulon, C; Dollé, F; Kassiou, M; Lagnel, B; Ottaviani, M; Roger, G; Valette, H, 2003
)
0.32
" In mouse hippocampal slices, sunifiram at 10-100 nM significantly enhanced LTP in a bell-shaped dose-response relationship which peaked at 10 nM."( Novel nootropic drug sunifiram enhances hippocampal synaptic efficacy via glycine-binding site of N-methyl-D-aspartate receptor.
Fukunaga, K; Moriguchi, S; Narahashi, T; Tanaka, T, 2013
)
0.39
"After intrathecally injecting the rats with five different doses of each drug, the dose-response curves of ifenprodil and bupivacaine were constructed to obtain the 50% effective dose (ED50)."( Ifenprodil for prolonged spinal blockades of motor function and nociception in rats.
Chen, YW; Chiu, CC; Hung, CH; Wang, JJ; Wang, JN, 2016
)
2.09
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
piperidines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (5)

PathwayProteinsCompounds
Neuronal System16650
Transmission across Chemical Synapses12250
Neurotransmitter receptors and postsynaptic signal transmission7820
Activation of NMDA receptors and postsynaptic events4013
Unblocking of NMDA receptors, glutamate binding and activation15

Protein Targets (49)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency30.90080.002541.796015,848.9004AID1347398
ATAD5 protein, partialHomo sapiens (human)Potency15.66940.004110.890331.5287AID493106; AID493107
TDP1 proteinHomo sapiens (human)Potency14.77520.000811.382244.6684AID686978; AID686979
AR proteinHomo sapiens (human)Potency33.49150.000221.22318,912.5098AID743042; AID743054
progesterone receptorHomo sapiens (human)Potency29.84930.000417.946075.1148AID1346784
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency20.30300.01237.983543.2770AID1346984; AID1645841
estrogen nuclear receptor alphaHomo sapiens (human)Potency24.11230.000229.305416,493.5996AID743075; AID743080; AID743091
cytochrome P450 2D6Homo sapiens (human)Potency0.69180.00108.379861.1304AID1645840
glucocerebrosidaseHomo sapiens (human)Potency35.48130.01268.156944.6684AID2101
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.63100.035520.977089.1251AID504332
D(1A) dopamine receptorHomo sapiens (human)Potency3.94280.02245.944922.3872AID488981; AID488982; AID488983
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency1.12200.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency23.71010.000323.4451159.6830AID743065; AID743067
ras-related protein Rab-9AHomo sapiens (human)Potency58.04790.00022.621531.4954AID485297
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency11.03370.00378.618923.2809AID2667; AID2668
gemininHomo sapiens (human)Potency33.72060.004611.374133.4983AID624296; AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency25.57480.005612.367736.1254AID624032
lamin isoform A-delta10Homo sapiens (human)Potency35.48130.891312.067628.1838AID1487
D(1A) dopamine receptorSus scrofa (pig)Potency10.39920.00378.108123.2809AID2667
Ataxin-2Homo sapiens (human)Potency28.18380.011912.222168.7989AID588378
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutamate receptor ionotropic, NMDA 2DHomo sapiens (human)IC50 (µMol)75.90000.00401.73519.8000AID1512710
Muscarinic acetylcholine receptor M3Rattus norvegicus (Norway rat)IC50 (µMol)1.00000.00052.891925.1700AID142907
D(2) dopamine receptorHomo sapiens (human)IC50 (µMol)1.00000.00000.74728.0000AID64128
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.10500.00021.874210.0000AID36316; AID36843
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.10500.00021.270410.0000AID36316; AID36843
Delta-type opioid receptorRattus norvegicus (Norway rat)IC50 (µMol)1.00000.00030.38877.0000AID149325
Histamine H1 receptorHomo sapiens (human)IC50 (µMol)1.00000.00000.44365.1768AID87682
Mu-type opioid receptorHomo sapiens (human)IC50 (µMol)1.00000.00010.813310.0000AID149325
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)IC50 (µMol)0.16800.00071.600310.0000AID144751; AID391045
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)Ki0.14320.00030.86666.6900AID1876638
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.10500.00001.819410.0000AID36316; AID36843
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)IC50 (µMol)0.26300.00071.630610.0000AID144751
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)Ki0.14320.00030.68056.6900AID1876638
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)IC50 (µMol)0.16800.00061.525710.0000AID144751; AID391045
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)Ki0.04610.00030.70716.6900AID1060809; AID1876638; AID526573
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)IC50 (µMol)0.26300.00071.747210.0000AID144751
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)Ki0.14320.00030.81966.6900AID1876638
Glutamate receptor ionotropic, NMDA 1Homo sapiens (human)IC50 (µMol)0.20390.00101.88779.8000AID332033; AID502295; AID606302; AID606399; AID606401; AID730403
Glutamate receptor ionotropic, NMDA 1Homo sapiens (human)Ki0.01000.00120.48246.0000AID1407750; AID538755
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)0.10000.00091.901410.0000AID576612
Glutamate receptor ionotropic, NMDA 2AHomo sapiens (human)IC50 (µMol)39.50000.00101.99589.8000AID1512707
Glutamate receptor ionotropic, NMDA 2BHomo sapiens (human)IC50 (µMol)0.15190.00401.33259.8000AID1064684; AID1512708; AID1637895; AID332033; AID502295; AID606302; AID606399; AID606401; AID730403
Glutamate receptor ionotropic, NMDA 2BHomo sapiens (human)Ki0.01000.00120.32686.0000AID1174070; AID1403510; AID1407750; AID1415567; AID1637892; AID1650557; AID1655193; AID1690208; AID1865090; AID538755
Glutamate receptor ionotropic, NMDA 2CHomo sapiens (human)IC50 (µMol)29.10000.00401.86339.8000AID1512709
Sigma intracellular receptor 2Rattus norvegicus (Norway rat)Ki0.09800.00241.10509.3000AID1690210; AID1865087
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomeraseCavia porcellus (domestic guinea pig)Ki0.00270.00270.00270.0027AID205913
Sigma non-opioid intracellular receptor 1Cavia porcellus (domestic guinea pig)Ki0.10510.00000.338510.0000AID1060809; AID1174070; AID1369086; AID1378105; AID1403514; AID1407753; AID1421275; AID1519019; AID1637893; AID1690209; AID1865086; AID538759
DMus musculus (house mouse)IC50 (µMol)1.00000.75000.75000.7500AID61833
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)IC50 (µMol)0.26300.00071.741110.0000AID144751
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)Ki0.14320.00030.70726.6900AID1876638
5-hydroxytryptamine receptor 1AMus musculus (house mouse)IC50 (µMol)0.23800.00210.35812.0000AID4461
5-hydroxytryptamine receptor 2ABos taurus (cattle)IC50 (µMol)0.61000.00902.71404.3652AID5131
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)IC50 (µMol)0.26300.00071.741110.0000AID144751
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)Ki0.14320.00030.70726.6900AID1876638
Sigma non-opioid intracellular receptor 1Homo sapiens (human)IC50 (µMol)0.00390.00030.70285.3660AID229210
Sigma non-opioid intracellular receptor 1Rattus norvegicus (Norway rat)Ki0.00490.00030.26715.0700AID204312
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)IC50 (µMol)0.26300.00071.741110.0000AID144751
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)Ki0.14320.00030.70726.6900AID1876638
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (199)

Processvia Protein(s)Taxonomy
startle responseGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
brain developmentGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
adult locomotory behaviorGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
calcium-mediated signalingGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
regulation of synaptic plasticityGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
regulation of neuronal synaptic plasticityGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
regulation of sensory perception of painGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
calcium ion transmembrane import into cytosolGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
excitatory chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
regulation of presynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
regulation of monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
cellular response to L-glutamateGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
positive regulation of excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
long-term synaptic potentiationGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
temperature homeostasisD(2) dopamine receptorHomo sapiens (human)
response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein phosphorylationD(2) dopamine receptorHomo sapiens (human)
response to amphetamineD(2) dopamine receptorHomo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressureD(2) dopamine receptorHomo sapiens (human)
regulation of heart rateD(2) dopamine receptorHomo sapiens (human)
regulation of sodium ion transportD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(2) dopamine receptorHomo sapiens (human)
positive regulation of neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
positive regulation of receptor internalizationD(2) dopamine receptorHomo sapiens (human)
autophagyD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
neuron-neuron synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
axonogenesisD(2) dopamine receptorHomo sapiens (human)
synapse assemblyD(2) dopamine receptorHomo sapiens (human)
sensory perception of smellD(2) dopamine receptorHomo sapiens (human)
long-term memoryD(2) dopamine receptorHomo sapiens (human)
grooming behaviorD(2) dopamine receptorHomo sapiens (human)
locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
adult walking behaviorD(2) dopamine receptorHomo sapiens (human)
protein localizationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell population proliferationD(2) dopamine receptorHomo sapiens (human)
associative learningD(2) dopamine receptorHomo sapiens (human)
visual learningD(2) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(2) dopamine receptorHomo sapiens (human)
response to light stimulusD(2) dopamine receptorHomo sapiens (human)
response to toxic substanceD(2) dopamine receptorHomo sapiens (human)
response to iron ionD(2) dopamine receptorHomo sapiens (human)
response to inactivityD(2) dopamine receptorHomo sapiens (human)
Wnt signaling pathwayD(2) dopamine receptorHomo sapiens (human)
striatum developmentD(2) dopamine receptorHomo sapiens (human)
orbitofrontal cortex developmentD(2) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(2) dopamine receptorHomo sapiens (human)
adenohypophysis developmentD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell migrationD(2) dopamine receptorHomo sapiens (human)
peristalsisD(2) dopamine receptorHomo sapiens (human)
auditory behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of synaptic transmission, GABAergicD(2) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(2) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
response to histamineD(2) dopamine receptorHomo sapiens (human)
response to nicotineD(2) dopamine receptorHomo sapiens (human)
positive regulation of urine volumeD(2) dopamine receptorHomo sapiens (human)
positive regulation of renal sodium excretionD(2) dopamine receptorHomo sapiens (human)
positive regulation of multicellular organism growthD(2) dopamine receptorHomo sapiens (human)
response to cocaineD(2) dopamine receptorHomo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleepD(2) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(2) dopamine receptorHomo sapiens (human)
drinking behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(2) dopamine receptorHomo sapiens (human)
response to morphineD(2) dopamine receptorHomo sapiens (human)
pigmentationD(2) dopamine receptorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(2) dopamine receptorHomo sapiens (human)
negative regulation of innate immune responseD(2) dopamine receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IID(2) dopamine receptorHomo sapiens (human)
negative regulation of insulin secretionD(2) dopamine receptorHomo sapiens (human)
acid secretionD(2) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(2) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(2) dopamine receptorHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityD(2) dopamine receptorHomo sapiens (human)
response to axon injuryD(2) dopamine receptorHomo sapiens (human)
branching morphogenesis of a nerveD(2) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(2) dopamine receptorHomo sapiens (human)
epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(2) dopamine receptorHomo sapiens (human)
release of sequestered calcium ion into cytosolD(2) dopamine receptorHomo sapiens (human)
dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of synapse structural plasticityD(2) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(2) dopamine receptorHomo sapiens (human)
excitatory postsynaptic potentialD(2) dopamine receptorHomo sapiens (human)
positive regulation of growth hormone secretionD(2) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeD(2) dopamine receptorHomo sapiens (human)
regulation of locomotion involved in locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
negative regulation of cellular response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor productionD(2) dopamine receptorHomo sapiens (human)
positive regulation of long-term synaptic potentiationD(2) dopamine receptorHomo sapiens (human)
hyaloid vascular plexus regressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of neuron migrationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(2) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(2) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
inflammatory responseHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
memoryHistamine H1 receptorHomo sapiens (human)
visual learningHistamine H1 receptorHomo sapiens (human)
regulation of vascular permeabilityHistamine H1 receptorHomo sapiens (human)
positive regulation of vasoconstrictionHistamine H1 receptorHomo sapiens (human)
regulation of synaptic plasticityHistamine H1 receptorHomo sapiens (human)
cellular response to histamineHistamine H1 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H1 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMu-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
sensory perceptionMu-type opioid receptorHomo sapiens (human)
negative regulation of cell population proliferationMu-type opioid receptorHomo sapiens (human)
sensory perception of painMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
behavioral response to ethanolMu-type opioid receptorHomo sapiens (human)
positive regulation of neurogenesisMu-type opioid receptorHomo sapiens (human)
negative regulation of Wnt protein secretionMu-type opioid receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMu-type opioid receptorHomo sapiens (human)
calcium ion transmembrane transportMu-type opioid receptorHomo sapiens (human)
cellular response to morphineMu-type opioid receptorHomo sapiens (human)
regulation of cellular response to stressMu-type opioid receptorHomo sapiens (human)
regulation of NMDA receptor activityMu-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayMu-type opioid receptorHomo sapiens (human)
cellular response to amyloid-betaGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
monoatomic cation transportGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
brain developmentGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
visual learningGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
positive regulation of calcium ion transport into cytosolGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
propylene metabolic processGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calcium-mediated signalingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
regulation of membrane potentialGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
response to ethanolGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
regulation of synaptic plasticityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
regulation of neuronal synaptic plasticityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
protein heterotetramerizationGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calcium ion homeostasisGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calcium ion transmembrane import into cytosolGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
excitatory chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
positive regulation of reactive oxygen species biosynthetic processGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
regulation of monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
response to glycineGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
positive regulation of excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to amyloid-betaGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
startle responseGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
response to amphetamineGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
brain developmentGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
learning or memoryGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
memoryGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
visual learningGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
response to xenobiotic stimulusGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
response to woundingGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
sensory perception of painGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
calcium-mediated signalingGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
neurogenesisGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
protein catabolic processGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
sleepGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
directional locomotionGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
negative regulation of protein catabolic processGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
dopamine metabolic processGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
serotonin metabolic processGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
positive regulation of apoptotic processGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
response to ethanolGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
regulation of synaptic plasticityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
regulation of neuronal synaptic plasticityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
activation of cysteine-type endopeptidase activityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
calcium ion transmembrane import into cytosolGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
excitatory chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
protein localization to postsynaptic membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
regulation of monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
positive regulation of excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
long-term synaptic potentiationGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
brain developmentGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
learning or memoryGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
calcium-mediated signalingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
response to ethanolGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
regulation of synaptic plasticityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
regulation of neuronal synaptic plasticityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
protein heterotetramerizationGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
calcium ion transmembrane import into cytosolGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
excitatory chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
regulation of presynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
negative regulation of dendritic spine maintenanceGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
regulation of monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
positive regulation of excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
positive regulation of cysteine-type endopeptidase activityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
long-term synaptic potentiationGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
brain developmentGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
response to woundingGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
calcium-mediated signalingGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
directional locomotionGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
negative regulation of protein catabolic processGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
regulation of synaptic plasticityGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
regulation of neuronal synaptic plasticityGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
neuromuscular process controlling balanceGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
calcium ion transmembrane import into cytosolGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
excitatory chemical synaptic transmissionGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
protein localization to postsynaptic membraneGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
regulation of monoatomic cation transmembrane transportGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
positive regulation of excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
long-term synaptic potentiationGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
synaptic transmission, glutamatergicGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
excitatory postsynaptic potentialGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
glycolytic process5-hydroxytryptamine receptor 2ABos taurus (cattle)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2ABos taurus (cattle)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2ABos taurus (cattle)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2ABos taurus (cattle)
protein localization to cytoskeleton5-hydroxytryptamine receptor 2ABos taurus (cattle)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2ABos taurus (cattle)
positive regulation of glycolytic process5-hydroxytryptamine receptor 2ABos taurus (cattle)
positive regulation of peptidyl-tyrosine phosphorylation5-hydroxytryptamine receptor 2ABos taurus (cattle)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2ABos taurus (cattle)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
lipid transportSigma non-opioid intracellular receptor 1Homo sapiens (human)
nervous system developmentSigma non-opioid intracellular receptor 1Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwaySigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of neuron apoptotic processSigma non-opioid intracellular receptor 1Homo sapiens (human)
protein homotrimerizationSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (51)

Processvia Protein(s)Taxonomy
glutamate-gated receptor activityGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
protein bindingGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
glutamate bindingGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
voltage-gated monoatomic cation channel activityGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(2) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(2) dopamine receptorHomo sapiens (human)
protein bindingD(2) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(2) dopamine receptorHomo sapiens (human)
dopamine bindingD(2) dopamine receptorHomo sapiens (human)
ionotropic glutamate receptor bindingD(2) dopamine receptorHomo sapiens (human)
identical protein bindingD(2) dopamine receptorHomo sapiens (human)
heterocyclic compound bindingD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(2) dopamine receptorHomo sapiens (human)
histamine receptor activityHistamine H1 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H1 receptorHomo sapiens (human)
neurotransmitter receptor activityHistamine H1 receptorHomo sapiens (human)
G-protein alpha-subunit bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled receptor activityMu-type opioid receptorHomo sapiens (human)
beta-endorphin receptor activityMu-type opioid receptorHomo sapiens (human)
voltage-gated calcium channel activityMu-type opioid receptorHomo sapiens (human)
protein bindingMu-type opioid receptorHomo sapiens (human)
morphine receptor activityMu-type opioid receptorHomo sapiens (human)
G-protein beta-subunit bindingMu-type opioid receptorHomo sapiens (human)
neuropeptide bindingMu-type opioid receptorHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calcium channel activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
amyloid-beta bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calcium ion bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
protein bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
calmodulin bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
glycine bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
glutamate bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
protein-containing complex bindingGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
signaling receptor activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
ligand-gated monoatomic ion channel activityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
amyloid-beta bindingGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
protein bindingGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
zinc ion bindingGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
amyloid-beta bindingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
protein bindingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
zinc ion bindingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
glycine bindingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
glutamate bindingGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
NMDA glutamate receptor activityGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
protein bindingGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
glutamate-gated calcium ion channel activityGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2ABos taurus (cattle)
protein tyrosine kinase activator activity5-hydroxytryptamine receptor 2ABos taurus (cattle)
identical protein binding5-hydroxytryptamine receptor 2ABos taurus (cattle)
serotonin binding5-hydroxytryptamine receptor 2ABos taurus (cattle)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2ABos taurus (cattle)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
G protein-coupled opioid receptor activitySigma non-opioid intracellular receptor 1Homo sapiens (human)
protein bindingSigma non-opioid intracellular receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (61)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
postsynaptic membraneGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
presynaptic active zone membraneGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
hippocampal mossy fiber to CA3 synapseGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
glutamatergic synapseGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2DHomo sapiens (human)
Golgi membraneD(2) dopamine receptorHomo sapiens (human)
acrosomal vesicleD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
ciliumD(2) dopamine receptorHomo sapiens (human)
lateral plasma membraneD(2) dopamine receptorHomo sapiens (human)
endocytic vesicleD(2) dopamine receptorHomo sapiens (human)
axonD(2) dopamine receptorHomo sapiens (human)
dendriteD(2) dopamine receptorHomo sapiens (human)
synaptic vesicle membraneD(2) dopamine receptorHomo sapiens (human)
sperm flagellumD(2) dopamine receptorHomo sapiens (human)
dendritic spineD(2) dopamine receptorHomo sapiens (human)
perikaryonD(2) dopamine receptorHomo sapiens (human)
axon terminusD(2) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(2) dopamine receptorHomo sapiens (human)
ciliary membraneD(2) dopamine receptorHomo sapiens (human)
non-motile ciliumD(2) dopamine receptorHomo sapiens (human)
dopaminergic synapseD(2) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(2) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(2) dopamine receptorHomo sapiens (human)
presynaptic membraneD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
cytosolHistamine H1 receptorHomo sapiens (human)
plasma membraneHistamine H1 receptorHomo sapiens (human)
synapseHistamine H1 receptorHomo sapiens (human)
dendriteHistamine H1 receptorHomo sapiens (human)
plasma membraneHistamine H1 receptorHomo sapiens (human)
endosomeMu-type opioid receptorHomo sapiens (human)
endoplasmic reticulumMu-type opioid receptorHomo sapiens (human)
Golgi apparatusMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
axonMu-type opioid receptorHomo sapiens (human)
dendriteMu-type opioid receptorHomo sapiens (human)
perikaryonMu-type opioid receptorHomo sapiens (human)
synapseMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
neuron projectionMu-type opioid receptorHomo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
cytoplasmGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
synaptic vesicleGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
cell surfaceGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
postsynaptic densityGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
dendriteGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
neuron projectionGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
synaptic cleftGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
terminal boutonGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
dendritic spineGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
synapseGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
postsynaptic membraneGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
excitatory synapseGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
synaptic membraneGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
synapseGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
neuron projectionGlutamate receptor ionotropic, NMDA 1Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
synaptic vesicleGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
cell surfaceGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
postsynaptic densityGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
cytoplasmic vesicle membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
presynaptic membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
dendritic spineGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
postsynaptic membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
synaptic membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
glutamatergic synapseGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, NMDA 2AHomo sapiens (human)
cytoplasmGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
lysosomeGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
late endosomeGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
cytoskeletonGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
cell surfaceGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
postsynaptic densityGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
neuron projectionGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
postsynaptic membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
synaptic membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, NMDA 2BHomo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
NMDA selective glutamate receptor complexGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
postsynaptic membraneGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
glutamatergic synapseGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
postsynaptic density membraneGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
plasma membraneGlutamate receptor ionotropic, NMDA 2CHomo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
caveola5-hydroxytryptamine receptor 2ABos taurus (cattle)
axon5-hydroxytryptamine receptor 2ABos taurus (cattle)
cytoplasmic vesicle5-hydroxytryptamine receptor 2ABos taurus (cattle)
presynapse5-hydroxytryptamine receptor 2ABos taurus (cattle)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2ABos taurus (cattle)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
nuclear envelopeSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear inner membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear outer membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid dropletSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytosolSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic densitySigma non-opioid intracellular receptor 1Homo sapiens (human)
membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
growth coneSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytoplasmic vesicleSigma non-opioid intracellular receptor 1Homo sapiens (human)
anchoring junctionSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic density membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (206)

Assay IDTitleYearJournalArticle
AID1409614Overall antiviral activity against SARS-CoV-2 (isolate France/IDF0372/2020) in the Vero E6 cell line at 48 h based on three assays 1) detection of viral RNA by qRT-PCR (targeting the N-gene), 2) plaque assay using lysate 3 days after addition of compound 2020Nature, 07, Volume: 583, Issue:7816
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID1369086Displacement of [3H]-(+)-Pentazocine from sigma 1 receptor in guinea pig brain cortex membranes after 120 mins by scintillation counting analysis2018Bioorganic & medicinal chemistry, 01-15, Volume: 26, Issue:2
2-Methyltetrahydro-3-benzazepin-1-ols - The missing link in SAR of GluN2B selective NMDA receptor antagonists.
AID392779Displacement of [3H]ifenprodil from NMDA NR2B receptor in Wistar rat cerebral cortex membrane2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
Development of 3-substituted-1H-indole derivatives as NR2B/NMDA receptor antagonists.
AID1369085Displacement of [3H]-ifenprodil from recombinant human GluN1a/GluN2B expressed in L(tk-) cell membranes after 120 mins by scintillation counting analysis2018Bioorganic & medicinal chemistry, 01-15, Volume: 26, Issue:2
2-Methyltetrahydro-3-benzazepin-1-ols - The missing link in SAR of GluN2B selective NMDA receptor antagonists.
AID348128Cytotoxicity against human PC3 cells assessed as LDH release at 100 uM after 24 hrs relative to untreated control2008Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23
Novel 4-(4-aryl)cyclohexyl-1-(2-pyridyl)piperazines as Delta(8)-Delta(7) sterol isomerase (emopamil binding protein) selective ligands with antiproliferative activity.
AID730398Selectivity ratio of IC50 for human GluN2C subunit containing NMDA receptor to IC50 for human GluN2B subunit containing NMDA receptor2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.
AID4461Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Separation of alpha 1 adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds.
AID634764Displacement of [3H]-emopamil from delta(8)-delta(7) sterol isomerase in guinea pig liver membranes2011Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24
Synthesis and binding assays of novel 3,3-dimethylpiperidine derivatives with various lipophilicities as σ₁ receptor ligands.
AID1064684Inhibition of NMDA receptor GluN2B subunit (unknown origin)2014Bioorganic & medicinal chemistry, Feb-01, Volume: 22, Issue:3
Synthesis, modelling and biological characterization of 3-substituted-1H-indoles as ligands of GluN2B-containing N-methyl-d-aspartate receptors.
AID427337Displacement of [3H](+)-pentazocine from sigma1 receptor in rat liver membrane by liquid scintillation counting2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Synthesis, biological evaluation, and three-dimensional in silico pharmacophore model for sigma(1) receptor ligands based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives.
AID332029Displacement of [3H]ifenprodil from rat brain membrane NR2B receptor relative to ifenprodil2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
Reactive derivatives for affinity labeling in the ifenprodil site of NMDA receptors.
AID437518Displacement of [3H](+/-)-emopamil from EBP in Dunkin guinea pig liver membrane by radioreceptor binding assay2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Exploring the importance of piperazine N-atoms for sigma(2) receptor affinity and activity in a series of analogs of 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28).
AID5131Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Separation of alpha 1 adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds.
AID1650559Displacement of [3H]-(+)-pentazocine from sigma1 receptor in guinea pig brain membranes incubated for 120 mins by scintillation counting method2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Thiophene bioisosteres of GluN2B selective NMDA receptor antagonists: Synthesis and pharmacological evaluation of [7]annuleno[b]thiophen-6-amines.
AID1774076Inhibition of 8-anilinonaphthalene-l-sulfonic acid binding to TTR V3OM mutant (unknown origin) expressed in Escherichia coli at 400 uM incubated for 1 hr in presence of 75 uM ANS by fluorescence method (Rvb = 91 +/- 0.92%)2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID502293Antagonist activity at wild type NR1/NR2B receptor expressed in Xenopus oocytes assessed as ratio of residual current induced by agonist in presence of compound to residual current induced by agonist alone at 10 uM by two-electrode voltage-clamp method2010Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18
Identification of a novel NR2B-selective NMDA receptor antagonist using a virtual screening approach.
AID1519020Displacement of [3H]di-o-tolylguanidine from sigma2 receptor in rat liver membranes measured after 120 mins by solid scintillation counting method
AID538763Half life in mouse liver microsomes2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Conformationally constrained NR2B selective NMDA receptor antagonists derived from ifenprodil: Synthesis and biological evaluation of tetrahydro-3-benzazepine-1,7-diols.
AID521216Antiproliferative activity against human fetal neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1415570Displacement of [3H]-di-o-tolylguanidine from sigma 2 receptor in rat liver membranes after 120 mins by scintillation counting analysis2017MedChemComm, May-01, Volume: 8, Issue:5
Do GluN2B subunit containing NMDA receptors tolerate a fluorine atom in the phenylalkyl side chain?
AID1415567Displacement of [3H]-ifenprodil from GluN2B receptor (unknown origin) expressed in mouse L (tk-) cell membranes after 120 mins by scintillation counting method2017MedChemComm, May-01, Volume: 8, Issue:5
Do GluN2B subunit containing NMDA receptors tolerate a fluorine atom in the phenylalkyl side chain?
AID502294Antagonist activity at NR1/NR2B NTD truncated mutant receptor expressed in Xenopus oocytes assessed as ratio of residual current induced by agonist in presence of compound to residual current induced by agonist alone at 10 uM by two-electrode voltage-clam2010Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18
Identification of a novel NR2B-selective NMDA receptor antagonist using a virtual screening approach.
AID1876644Neuroprotective activity in Sprague-Dawley rat model of middle cerebral artery occlusion-induced ischemia-reperfusion injury assessed as decrease in cerebral infarction rate at 20 mg/kg, po measured 24 hrs post injury by TTC staining based histological an2022European journal of medicinal chemistry, Jan-05, Volume: 227Discovery of novel brain-penetrant GluN2B NMDAR antagonists via pharmacophore-merging strategy as anti-stroke therapeutic agents.
AID1512708Negative allosteric modulation of human GluN2B receptor expressed in xenopus laevis oocytes assessed as reduction in 3 uM glycine-induced channel current at -40 mV holding potential by two electrode voltage clamp method2019Journal of medicinal chemistry, 01-10, Volume: 62, Issue:1
Positive and Negative Allosteric Modulators of N-Methyl-d-aspartate (NMDA) Receptors: Structure-Activity Relationships and Mechanisms of Action.
AID502298Antagonist activity at wild type NR1/NR2B receptor expressed in Xenopus oocytes assessed as inhibition of agonist-induced current amplitude at 10 uM by two-electrode voltage-clamp method2010Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18
Identification of a novel NR2B-selective NMDA receptor antagonist using a virtual screening approach.
AID521224Induction of apoptosis in mouse neural precursor cell assessed as increase in caspase-3/7 activation at 3 uM after 2 days2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID205913Inhibition of [3H]-emopamil binding to Sterol delta 8-delta 7 isomerase in guinea pig liver membrane2003Journal of medicinal chemistry, May-22, Volume: 46, Issue:11
Synthesis of chiral 1-[omega-(4-chlorophenoxy)alkyl]-4-methylpiperidines and their biological evaluation at sigma1, sigma2, and sterol delta8-delta7 isomerase sites.
AID730403Inhibition of GluN1/GluN2B receptor (unknown origin) expressed in Xenopus oocytes by voltage clamp assay2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.
AID144751N-methyl-D-aspartate glutamate receptor antagonistic activity in cell culture(CC)model1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Separation of alpha 1 adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds.
AID707048Neuroprotective activity in human SH-SY5Y cells assessed as protection against NMDA-induced cell death after 6 hrs by MTS assay2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease.
AID1876643Antagonist activity at GluN1/GluN2D NMDA receptor (unknown origin) transfected in HEK293 cells assessed as inhibition of glycine induced current response at 10 uM in presence of L-glutamate by patch-clamp method2022European journal of medicinal chemistry, Jan-05, Volume: 227Discovery of novel brain-penetrant GluN2B NMDAR antagonists via pharmacophore-merging strategy as anti-stroke therapeutic agents.
AID256860Displacement of [3H](+/-)-emopamil from delta8-delta7 sterol isomerase (SI) site in guinea pig liver membranes2005Journal of medicinal chemistry, Dec-29, Volume: 48, Issue:26
Methyl substitution on the piperidine ring of N-[omega-(6-methoxynaphthalen-1-yl)alkyl] derivatives as a probe for selective binding and activity at the sigma(1) receptor.
AID1421277Selectivity ratio of Ki for S2R in rat liver membranes to Ki for S2R in guinea pig brain cortex membranes2018European journal of medicinal chemistry, Oct-05, Volume: 158Identification of dual Sigma1 receptor modulators/acetylcholinesterase inhibitors with antioxidant and neurotrophic properties, as neuroprotective agents.
AID1378106Displacement of [3H]DTG from sigma2 receptor in rat liver membranes after 120 mins by microbeta scintillation counting method2017European journal of medicinal chemistry, Sep-29, Volume: 138Deconstruction - reconstruction approach to analyze the essential structural elements of tetrahydro-3-benzazepine-based antagonists of GluN2B subunit containing NMDA receptors.
AID538765Half life in human liver microsomes2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Conformationally constrained NR2B selective NMDA receptor antagonists derived from ifenprodil: Synthesis and biological evaluation of tetrahydro-3-benzazepine-1,7-diols.
AID526573Displacement of [3H]ifenprodil from NR2B receptor in rat cortical synaptic membranes2010Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21
Synthesis and biological evaluation of radio-iodinated benzimidazoles as SPECT imaging agents for NR2B subtype of NMDA receptor.
AID297869Displacement of [3H]emopamil from Delta-(8)-Delta-(7) sterol isomerase in guinea pig liver membrane2007Journal of medicinal chemistry, Sep-20, Volume: 50, Issue:19
Design and evaluation of naphthol- and carbazole-containing fluorescent sigma ligands as potential probes for receptor binding studies.
AID521213Induction of apoptosis in mouse neural precursor cell assessed as caspase-3/7 activation at 3 uM after 12 hrs2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID730402Neuroprotective activity in rat Cortical neuron assessed as protection from glutamate-induced neurotoxicity treated after glutamate-challenge by lactate dehydrogenase assay2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.
AID1655192Displacement of [3H]-Di-o-tolylguanidine from sigma-2 receptor in rat liver membranes after 120 mins by scintillation counting method2020ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5
Synthesis, Cytotoxicity Evaluation, and Computational Insights of Novel 1,4-Diazepane-Based Sigma Ligands.
AID332033Inhibition of NR1/NR2B receptor expressed in xenopus oocytes assessed as effect on L-glutamate and glycine-induced current response2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
Reactive derivatives for affinity labeling in the ifenprodil site of NMDA receptors.
AID1064682Displacement of [3H]Ifenprodil from NMDA receptor GluN2B subunit in Wistar rat cerebral cortex2014Bioorganic & medicinal chemistry, Feb-01, Volume: 22, Issue:3
Synthesis, modelling and biological characterization of 3-substituted-1H-indoles as ligands of GluN2B-containing N-methyl-d-aspartate receptors.
AID1650560Displacement of [3H]-di-o-tolylguanidine from sigma2 receptor in rat liver membranes incubated for 120 mins in the presence of sigma1 receptor ligand (+)-pentazocine by scintillation counting method2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Thiophene bioisosteres of GluN2B selective NMDA receptor antagonists: Synthesis and pharmacological evaluation of [7]annuleno[b]thiophen-6-amines.
AID348123Displacement of [3H]-DTG from sigma 2-type opioid receptor in rat liver membrane in presence of (+)-pentazocine2008Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23
Novel 4-(4-aryl)cyclohexyl-1-(2-pyridyl)piperazines as Delta(8)-Delta(7) sterol isomerase (emopamil binding protein) selective ligands with antiproliferative activity.
AID235213Therapeutic index is the ratio of IC50 value for Alpha-1 adrenergic receptor to that for N-methyl-D-aspartate glutamate receptor1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Separation of alpha 1 adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds.
AID332034Inhibition of NR1/NR2B receptor expressed in xenopus oocytes assessed as effect on L-glutamate and glycine-induced current response relative to ifenprodil2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
Reactive derivatives for affinity labeling in the ifenprodil site of NMDA receptors.
AID521222Inhibition of neurosphere formation of mouse neural precursor cells pretreated for 7 days at antiproliferative EC75 level upon reculture in absence of compound by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1690211Cytoprotective activity against glutamate/glycine-induced cell death in mouse L-M(TK-) cells assessed as increase in cell viability incubated for 30 mins followed by glutamate/glycine stimulation and measured after 6 hrs by LDH assay
AID1060811Displacement of [3H]ifenprodil from Wistar rat cerebral cortex glutamate NMDA receptor GluN2B subunit after 120 mins by scintillation counting analysis2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
From NMDA receptor antagonists to discovery of selective σ₂ receptor ligands.
AID1876640Antagonist activity at GluN1/GluN2A NMDA receptor (unknown origin) transfected in HEK293 cells assessed as inhibition of glycine induced current response at 10 uM in presence of L-glutamate by patch-clamp method2022European journal of medicinal chemistry, Jan-05, Volume: 227Discovery of novel brain-penetrant GluN2B NMDAR antagonists via pharmacophore-merging strategy as anti-stroke therapeutic agents.
AID61833Compound was tested for the binding affinity against dopamine receptor D1 by using [3H]-SCH- 23390 as radioligand1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Separation of alpha 1 adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds.
AID1174070Displacement of [3H]ifenprodil from human GluN2B expressed in mouse L(tk-) cells co-expressing GluN1a after 120 mins by scintillation counting method2014Bioorganic & medicinal chemistry, Dec-01, Volume: 22, Issue:23
Synthesis, GluN2B affinity and selectivity of benzo[7]annulen-7-amines.
AID391045Inhibition of rat recombinant NR1/NR2B receptor expressed in Xenopus oocytes assessed as inhibition of glutamate and glycine-induced evoked current by two electrode voltage clamp method2008Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18
Enantiomeric propanolamines as selective N-methyl-D-aspartate 2B receptor antagonists.
AID1378104Displacement of [3H](+)-MK801 from PCP binding site of NMDA receptor in pig brain cortex membranes after 120 mins by microbeta scintillation counting method2017European journal of medicinal chemistry, Sep-29, Volume: 138Deconstruction - reconstruction approach to analyze the essential structural elements of tetrahydro-3-benzazepine-based antagonists of GluN2B subunit containing NMDA receptors.
AID606302Antagonist activity against NR1a/NR2B receptor transfected in human HEK293 cells assessed as inhibition of NMDA-induced Ca2+ influx2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Synthesis, evaluation and metabolic studies of radiotracers containing a 4-(4-[18F]-fluorobenzyl)piperidin-1-yl moiety for the PET imaging of NR2B NMDA receptors.
AID1876639Neuroprotective activity in Sprague-Dawley rat model of middle cerebral artery occlusion-induced ischemia-reperfusion injury assessed as decrease in neurological score at 20 mg/kg, po measured 24 hrs post injury by TTC staining based histological analysis2022European journal of medicinal chemistry, Jan-05, Volume: 227Discovery of novel brain-penetrant GluN2B NMDAR antagonists via pharmacophore-merging strategy as anti-stroke therapeutic agents.
AID1279132Displacement of [3H]ifenprodil from Wistar rat cerebral cortex GluN2B receptor after 120 mins2016Bioorganic & medicinal chemistry, Apr-01, Volume: 24, Issue:7
Structure-guided design of new indoles as negative allosteric modulators (NAMs) of N-methyl-D-aspartate receptor (NMDAR) containing GluN2B subunit.
AID1690210Displacement of [3H]DTG from sigma 2 receptor in rat liver membranes incubated for 120 mins by scintillation counting method
AID1512707Negative allosteric modulation of human GluN2A receptor expressed in xenopus laevis oocytes assessed as reduction in 3 uM glycine-induced channel current at -40 mV holding potential by two electrode voltage clamp method2019Journal of medicinal chemistry, 01-10, Volume: 62, Issue:1
Positive and Negative Allosteric Modulators of N-Methyl-d-aspartate (NMDA) Receptors: Structure-Activity Relationships and Mechanisms of Action.
AID1690208Displacement of [3H]ifenprodil from human GluN2B expressed in mouse L(tk-) cell membranes co-expressing GluN1a incubated for 2 hrs by scintillation counting method
AID64128Compound was tested for the binding affinity against dopamine receptor D2 by using [3H]spiperone as radioligand1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Separation of alpha 1 adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds.
AID1876636Neuroprotective activity against NMDA-induced neurotoxicity in Sprague-Dawley rat hippocampal neurons assessed as increase in cell viability at 1 uM incubated for 18 hrs followed by NMDA addition and measured after 0.5 hrs by MTT assay2022European journal of medicinal chemistry, Jan-05, Volume: 227Discovery of novel brain-penetrant GluN2B NMDAR antagonists via pharmacophore-merging strategy as anti-stroke therapeutic agents.
AID1512710Negative allosteric modulation of human GluN2D receptor expressed in xenopus laevis oocytes assessed as reduction in 3 uM glycine-induced channel current at -40 mV holding potential by two electrode voltage clamp method2019Journal of medicinal chemistry, 01-10, Volume: 62, Issue:1
Positive and Negative Allosteric Modulators of N-Methyl-d-aspartate (NMDA) Receptors: Structure-Activity Relationships and Mechanisms of Action.
AID1637892Displacement of [3H]-ifenprodil from GluN2B (unknown origin) expressed in rat L(tk) cells measured after 120 mins by scintillation counting analysis2019MedChemComm, Feb-01, Volume: 10, Issue:2
Synthesis and receptor binding of thiophene bioisosteres of potent GluN2B ligands with a benzo[7]annulene-scaffold.
AID1421275Displacement of [3H](+)-pentazocine from S1R in guinea pig brain cortex membranes after 120 mins by scintillation counting assay2018European journal of medicinal chemistry, Oct-05, Volume: 158Identification of dual Sigma1 receptor modulators/acetylcholinesterase inhibitors with antioxidant and neurotrophic properties, as neuroprotective agents.
AID1060807Selectivity ratio of Ki for guinea pig brain sigma1 receptor to Ki for guinea pig brain sigma2 receptor2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
From NMDA receptor antagonists to discovery of selective σ₂ receptor ligands.
AID538764Half life in rat liver microsomes2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Conformationally constrained NR2B selective NMDA receptor antagonists derived from ifenprodil: Synthesis and biological evaluation of tetrahydro-3-benzazepine-1,7-diols.
AID606399Antagonist activity against NR1/NR2B receptor expressed in xenopus oocytes assessed as inhibition of NMDA induced Ca2+ influx2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Synthesis, evaluation and metabolic studies of radiotracers containing a 4-(4-[18F]-fluorobenzyl)piperidin-1-yl moiety for the PET imaging of NR2B NMDA receptors.
AID1519021Cytoprotection against glutamate/glycine-induced cytotoxicity against mouse LTK cells expressing GluN1a/GluN2B preincubated 30 mins followed by glutamate/glycine addition and measured after 6 hrs by LDH assay
AID1407753Displacement of [3H]-(+)-pentazocine from sigma1 receptor in guinea pig brain cortex membrane after 120 mins by scintillation counting method2018European journal of medicinal chemistry, Sep-05, Volume: 157Pyridine bioisosteres of potent GluN2B subunit containing NMDA receptor antagonists with benzo[7]annulene scaffold.
AID1378105Displacement of [3H]-(+)-pentazocine from sigma1 receptor in guinea pig brain cortex membranes after 120 mins by microbeta scintillation counting method2017European journal of medicinal chemistry, Sep-29, Volume: 138Deconstruction - reconstruction approach to analyze the essential structural elements of tetrahydro-3-benzazepine-based antagonists of GluN2B subunit containing NMDA receptors.
AID1774079Stabilization of TTR V3OM mutant (unknown origin) assessed as acid-mediated protein aggregation inhibition ratio at 10 uM incubated for 1 week by absorbance method2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID348127Selectivity ratio of Ki for sigma 2 receptor in rat liver membrane to Ki for EBP in guinea pig liver membrane2008Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23
Novel 4-(4-aryl)cyclohexyl-1-(2-pyridyl)piperazines as Delta(8)-Delta(7) sterol isomerase (emopamil binding protein) selective ligands with antiproliferative activity.
AID1690209Displacement of [3H]-(+)-pentazocine from Sigma1 receptor in guinea pig cortex membranes incubated for 120 mins by scintillation counting method
AID1403515Displacement of [3H]-di-o-tolylguanidine from sigma-2 receptor in rat liver membranes incubated for 120 mins measured for 5 mins by scintillation counting method
AID1415571Displacement of [3H](+)-Pentazocine from sigma 1 receptor in guinea pig brain membranes after 120 mins by scintillation counting analysis2017MedChemComm, May-01, Volume: 8, Issue:5
Do GluN2B subunit containing NMDA receptors tolerate a fluorine atom in the phenylalkyl side chain?
AID1378110Antagonist activity at GluN1A/GluN2A receptor (unknown origin) expressed in Xenopus laevis oocytes assessed as inhibition of glutamate/glycine-induced channel current at 1 uM at -70 mV holding potential by two electrode voltage clamp method relative to co2017European journal of medicinal chemistry, Sep-29, Volume: 138Deconstruction - reconstruction approach to analyze the essential structural elements of tetrahydro-3-benzazepine-based antagonists of GluN2B subunit containing NMDA receptors.
AID87682Compound was tested for the binding affinity against histamine H1 receptor by using [3H]mepyramine as radioligand1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Separation of alpha 1 adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds.
AID1407750Displacement of [3H]-ifenprodil from GluN1a/GluN2B (unknown origin) expressed in L(tk-) cell membranes after 120 mins by scintillation counting analysis2018European journal of medicinal chemistry, Sep-05, Volume: 157Pyridine bioisosteres of potent GluN2B subunit containing NMDA receptor antagonists with benzo[7]annulene scaffold.
AID1655191Displacement of [3H]-(+)pentazocine from sigma-1 receptor in guinea pig brain membranes after 120 mins by scintillation counting method2020ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5
Synthesis, Cytotoxicity Evaluation, and Computational Insights of Novel 1,4-Diazepane-Based Sigma Ligands.
AID1174074Displacement of [3H]DTG from sigma2 receptor in rat liver membranes after 180 mins by scintillation counting method2014Bioorganic & medicinal chemistry, Dec-01, Volume: 22, Issue:23
Synthesis, GluN2B affinity and selectivity of benzo[7]annulen-7-amines.
AID1876637Neuroprotective activity against NMDA-induced neurotoxicity in Sprague-Dawley rat hippocampal neurons assessed as increase in cell viability at 10 uM incubated for 18 hrs followed by NMDA addition and measured after 0.5 hrs by MTT assay2022European journal of medicinal chemistry, Jan-05, Volume: 227Discovery of novel brain-penetrant GluN2B NMDAR antagonists via pharmacophore-merging strategy as anti-stroke therapeutic agents.
AID332028Displacement of [3H]ifenprodil from rat brain membrane NR2B receptor2008Bioorganic & medicinal chemistry letters, May-01, Volume: 18, Issue:9
Reactive derivatives for affinity labeling in the ifenprodil site of NMDA receptors.
AID1407754Displacement of [3H]-di-o-tolylguanidine from sigma2 receptor in rat liver membranes incubated for 120 mins by scintillation counting method2018European journal of medicinal chemistry, Sep-05, Volume: 157Pyridine bioisosteres of potent GluN2B subunit containing NMDA receptor antagonists with benzo[7]annulene scaffold.
AID1655193Displacement of [3H]ifenprodil from GluN2B (unknown origin) expressed in mouse L(tk-) cell membranes co-expressing GluN1a incubated for 120 mins by scintillation counting method2020ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5
Synthesis, Cytotoxicity Evaluation, and Computational Insights of Novel 1,4-Diazepane-Based Sigma Ligands.
AID1378107Selectivity ratio of Ki for sigma1 receptor in guinea pig brain cortex membranes to Ki for recombinant human GluN1A/GluN2B receptor expressed in mouse L(tk-) cell membranes2017European journal of medicinal chemistry, Sep-29, Volume: 138Deconstruction - reconstruction approach to analyze the essential structural elements of tetrahydro-3-benzazepine-based antagonists of GluN2B subunit containing NMDA receptors.
AID1415568Displacement of [3H]-(+)-MK-801 from PCP binding site of NMDA receptor in pig brain cortex membranes after 90 mins by scintillation counting method2017MedChemComm, May-01, Volume: 8, Issue:5
Do GluN2B subunit containing NMDA receptors tolerate a fluorine atom in the phenylalkyl side chain?
AID1865086Displacement of [3H]-(+)-pentazocine from sigma1 receptor in guinea pig brain membrane measured after 120 mins by scintillation counting method
AID521211Cytotoxicity against mouse neural precursor cell assessed as decrease in viable cell number after 2 days by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1637894Displacement of [3H]di-o-tolylguanidine from sigma2 receptor in rat liver membranes measured after 120 mins by scintillation counting analysis2019MedChemComm, Feb-01, Volume: 10, Issue:2
Synthesis and receptor binding of thiophene bioisosteres of potent GluN2B ligands with a benzo[7]annulene-scaffold.
AID1064683Displacement of [3H]Ifenprodil from NMDA receptor GluN2B subunit in Wistar rat cerebral cortex at 0.1 uM2014Bioorganic & medicinal chemistry, Feb-01, Volume: 22, Issue:3
Synthesis, modelling and biological characterization of 3-substituted-1H-indoles as ligands of GluN2B-containing N-methyl-d-aspartate receptors.
AID707052Displacement of [3H]Ifenprodil from NMDAR-2B in Sprague-Dawley rat frontal cortex homogenates after 2 hrs by liquid scintillation counting2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease.
AID606401Antagonist activity at NR1/NR2B receptor assessed as inhibition of Glu/Gly induced Ca2+ influx2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Synthesis, evaluation and metabolic studies of radiotracers containing a 4-(4-[18F]-fluorobenzyl)piperidin-1-yl moiety for the PET imaging of NR2B NMDA receptors.
AID538755Displacement of [3H]ifenprodil from human recombinant NR1-1a/NR2B receptor expressed in mouse L(tk-) cells after 120 mins by scintillation counting2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Conformationally constrained NR2B selective NMDA receptor antagonists derived from ifenprodil: Synthesis and biological evaluation of tetrahydro-3-benzazepine-1,7-diols.
AID348126Selectivity ratio of Ki for sigma 1 receptor in guinea pig brain membrane without cerebellum to Ki for EBP in guinea pig liver membrane2008Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23
Novel 4-(4-aryl)cyclohexyl-1-(2-pyridyl)piperazines as Delta(8)-Delta(7) sterol isomerase (emopamil binding protein) selective ligands with antiproliferative activity.
AID730397Selectivity ratio of IC50 for human GluN2A subunit containing NMDA receptor to IC50 for human GluN2B subunit containing NMDA receptor2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.
AID709975Modulation of NMDA receptor GluN2B subunit in FVB mouse CA1 pyramidal neurons assessed as increase in EPSC amplitude at holding potential of -60 mV at 10 uM measured at 5 mins by patch clamp electrophysiological assay in presence of Mg2+ free ACSF contain2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Synthesis and biological characterization of 3-substituted 1H-indoles as ligands of GluN2B-containing N-methyl-D-aspartate receptors. Part 2.
AID1519017Displacement of [3H]ifenprodil from GluN1A/GluN2B (unknown origin) expressed in mouse L(tk-) cell membranes after 120 mins by solid scintillation counting method
AID348122Displacement of [3H](+)-pentazocine from sigma 1 receptor in guinea pig brain membrane without cerebellum2008Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23
Novel 4-(4-aryl)cyclohexyl-1-(2-pyridyl)piperazines as Delta(8)-Delta(7) sterol isomerase (emopamil binding protein) selective ligands with antiproliferative activity.
AID36843Compound was tested for the binding affinity against Alpha-1 adrenergic receptor1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Separation of alpha 1 adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds.
AID1865090Displacement of [3H]ifenprodil from recombinant human GluN2B NMDA receptor (unknown origin) expressed in dexamethasone-induced mouse L-M(TK-) cell after 120 mins by microbeta scintillation counting method
AID521225Decrease in nestin expression in mouse neural precursor cells at 5 uM after 2 days2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID149325Compound was tested for the binding affinity against opioid receptor mu by using [3H]naloxone as radioligand1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Separation of alpha 1 adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds.
AID1421246Negative allosteric modulation of GluN1a/GluN2B receptor (unknown origin) expressed in Xenopus laevis oocytes assessed as inhibition of (S)-glutamate/glycine-induced channel current at 10 uM at -70 mV holding potential by two electrode voltage clamp based2018European journal of medicinal chemistry, Oct-05, Volume: 158Systematic variation of the benzoylhydrazine moiety of the GluN2A selective NMDA receptor antagonist TCN-201.
AID36316Compound was tested for the binding affinity against Alpha-1 adrenergic receptor by using [3H]prazosin as radioligand1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Separation of alpha 1 adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds.
AID1650557Displacement of [3H]ifenprodil from human recombinant GluN2B expressed in mouse L(tk-) cell membranes co-expressing GluN1a incubated for 120 mins by scintillation counting method2020Bioorganic & medicinal chemistry, 01-15, Volume: 28, Issue:2
Thiophene bioisosteres of GluN2B selective NMDA receptor antagonists: Synthesis and pharmacological evaluation of [7]annuleno[b]thiophen-6-amines.
AID1876635Neuroprotective activity against NMDA-induced neurotoxicity in Sprague-Dawley rat hippocampal neurons assessed as increase in cell viability at 0.1 uM incubated for 18 hrs followed by NMDA addition and measured after 0.5 hrs by MTT assay2022European journal of medicinal chemistry, Jan-05, Volume: 227Discovery of novel brain-penetrant GluN2B NMDAR antagonists via pharmacophore-merging strategy as anti-stroke therapeutic agents.
AID1403518Antagonist activity at GluN2B/GluN1a receptor (unknown origin) expressed in mouse L(tk-) cells assessed as cytoprotection against glycine/(S)-glutamate-induced cell death preincubated for 30 mins followed by glycine/(S)-glutamate addition measured after 6
AID709978Displacement of [3H]ifenprodil from NMDA receptor GluN2B subunit in Wistar rat cerebral cortex after 120 mins2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Synthesis and biological characterization of 3-substituted 1H-indoles as ligands of GluN2B-containing N-methyl-D-aspartate receptors. Part 2.
AID1512709Negative allosteric modulation of human GluN2C receptor expressed in xenopus laevis oocytes assessed as reduction in 3 uM glycine-induced channel current at -40 mV holding potential by two electrode voltage clamp method2019Journal of medicinal chemistry, 01-10, Volume: 62, Issue:1
Positive and Negative Allosteric Modulators of N-Methyl-d-aspartate (NMDA) Receptors: Structure-Activity Relationships and Mechanisms of Action.
AID1403510Displacement of [3H]Ifenprodil from GluN2B receptor (unknown origin) expressed in mouse L(tk-) cell membranes incubated for 120 mins measured for 5 mins by scintillation counting method
AID1060808Displacement of [3H]DTG from guinea pig brain sigma2 receptor after 120 mins by scintillation counting analysis in presence of SKF10,0472014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
From NMDA receptor antagonists to discovery of selective σ₂ receptor ligands.
AID1421276Displacement of [3H]-DTG from S2R in rat liver membranes after 120 mins by scintillation counting assay2018European journal of medicinal chemistry, Oct-05, Volume: 158Identification of dual Sigma1 receptor modulators/acetylcholinesterase inhibitors with antioxidant and neurotrophic properties, as neuroprotective agents.
AID502295Antagonist activity at wild type NR1/NR2B receptor expressed in Xenopus oocytes assessed as inhibition of agonist-induced current amplitude by two-electrode voltage-clamp method2010Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18
Identification of a novel NR2B-selective NMDA receptor antagonist using a virtual screening approach.
AID538760Displacement of [3H]di-o-tolylguanidine from sigma2 receptor rat liver membranes after 180 mins scintillation counting2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Conformationally constrained NR2B selective NMDA receptor antagonists derived from ifenprodil: Synthesis and biological evaluation of tetrahydro-3-benzazepine-1,7-diols.
AID348121Displacement of [3H](-)-(S)-emopamil from EBP in guinea pig liver membrane2008Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23
Novel 4-(4-aryl)cyclohexyl-1-(2-pyridyl)piperazines as Delta(8)-Delta(7) sterol isomerase (emopamil binding protein) selective ligands with antiproliferative activity.
AID707053Displacement of [3H]MK-801 from NMDAR in Sprague-Dawley rat cerebral cortex homogenates after 2 hrs by liquid scintillation counting2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease.
AID348124Antiproliferative activity against human PC3 cells expressing EBP after 48 hrs by MTT assay2008Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23
Novel 4-(4-aryl)cyclohexyl-1-(2-pyridyl)piperazines as Delta(8)-Delta(7) sterol isomerase (emopamil binding protein) selective ligands with antiproliferative activity.
AID1774075Inhibition of 8-anilinonaphthalene-l-sulfonic acid binding to TTR V3OM mutant (unknown origin) expressed in Escherichia coli assessed as ANS saturation ratio at 400 uM incubated for 1 hr in presence of 7.5 uM ANS by fluorescence method (Rvb = 56 +/- 2.3%)2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1403514Displacement of [3H]-(+)-pentazocine from sigma-1 receptor in guinea pig brain cortex membranes incubated for 120 mins measured for 5 mins by scintillation counting method
AID1876638Displacement of [3H] ifenprodil from Wistar rat glutamate NMDA receptor incubated for 2 hrs by scintillation counting method2022European journal of medicinal chemistry, Jan-05, Volume: 227Discovery of novel brain-penetrant GluN2B NMDAR antagonists via pharmacophore-merging strategy as anti-stroke therapeutic agents.
AID1378102Displacement of [3H]ifenprodil from recombinant human GluN1A/GluN2B receptor expressed in mouse L(tk-) cell membranes after 120 mins by microbeta scintillation counting method2017European journal of medicinal chemistry, Sep-29, Volume: 138Deconstruction - reconstruction approach to analyze the essential structural elements of tetrahydro-3-benzazepine-based antagonists of GluN2B subunit containing NMDA receptors.
AID730396Selectivity ratio of IC50 for human GluN2D subunit containing NMDA receptor to IC50 for human GluN2B subunit containing NMDA receptor2013Journal of medicinal chemistry, Apr-25, Volume: 56, Issue:8
Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.
AID1378108Selectivity ratio of Ki for sigma2 receptor in rat liver membranes to Ki for recombinant human GluN1A/GluN2B receptor expressed in mouse L(tk-) cell membranes2017European journal of medicinal chemistry, Sep-29, Volume: 138Deconstruction - reconstruction approach to analyze the essential structural elements of tetrahydro-3-benzazepine-based antagonists of GluN2B subunit containing NMDA receptors.
AID1369084Displacement of [3H]-DTG from sigma 2 receptor in rat liver membranes after 120 mins by scintillation counting analysis2018Bioorganic & medicinal chemistry, 01-15, Volume: 26, Issue:2
2-Methyltetrahydro-3-benzazepin-1-ols - The missing link in SAR of GluN2B selective NMDA receptor antagonists.
AID606303Antagonist activity against NR1a/NR2A receptor transfected in human HEK293 cells assessed as inhibition of NMDA-induced Ca2+ influx at 10 uM2011European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
Synthesis, evaluation and metabolic studies of radiotracers containing a 4-(4-[18F]-fluorobenzyl)piperidin-1-yl moiety for the PET imaging of NR2B NMDA receptors.
AID521218Antiproliferative activity against human GBM2 cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1060809Displacement of [3H]-(+)-pentazocine from guinea pig brain sigma1 receptor after 150 mins by scintillation counting analysis2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
From NMDA receptor antagonists to discovery of selective σ₂ receptor ligands.
AID576612Inhibition of human ERG2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
AID1421280Displacement of [3H]-ifenprodil from GluN1a/GluN2B (unknown origin) expressed in mouse L(tk-) cell membranes after 120 mins by scintillation counting analysis2018European journal of medicinal chemistry, Oct-05, Volume: 158Identification of dual Sigma1 receptor modulators/acetylcholinesterase inhibitors with antioxidant and neurotrophic properties, as neuroprotective agents.
AID1774078Stabilization of TTR V3OM mutant (unknown origin) assessed as acid-mediated protein aggregation inhibition ratio at 4 uM incubated for 1 week by absorbance method2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Repositioning of the Anthelmintic Drugs Bithionol and Triclabendazole as Transthyretin Amyloidogenesis Inhibitors.
AID1865088Selectivity index, ratio of Ki for displacement of [3H]-(+)-pentazocine from sigma1 receptor in guinea pig brain membrane to Ki for displacement of [3H]DTG from sigma 2 receptor in rat liver membranes
AID1876642Antagonist activity at GluN1/GluN2C NMDA receptor (unknown origin) transfected in HEK293 cells assessed as inhibition of glycine induced current response at 10 uM in presence of L-glutamate by patch-clamp method2022European journal of medicinal chemistry, Jan-05, Volume: 227Discovery of novel brain-penetrant GluN2B NMDAR antagonists via pharmacophore-merging strategy as anti-stroke therapeutic agents.
AID1637895Displacement of [3H]-ifenprodil from GluN2B (unknown origin) expressed in mouse L(tk) cells after 120 mins by MicroBeta scintillation counting analysis2019MedChemComm, Feb-01, Volume: 10, Issue:2
Synthesis and receptor binding of thiophene bioisosteres of potent GluN2B ligands with a benzo[7]annulene-scaffold.
AID1690214Negative allosteric inhibition of GluN2B (unknown origin) expressed in Oocytes co-expressing GluN1a at 10 uM at -70 mV holding potential by two electrode voltage-clamp assay relative to control
AID142907Compound was tested for the binding affinity against muscarinic acetylcholine receptor
by using [3H]QNB as radioligand
1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Separation of alpha 1 adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds.
AID1519019Displacement of [3H]-(+)-pentazocine from sigma1 receptor in guinea pig brain cortex membranes incubated for 120 mins by solid scintillation counting method
AID521217Antiproliferative activity against human GBM1 cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID229210Compound was tested for the binding affinity against sigma receptor by using [3H]-+3PPP as radioligand1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
Separation of alpha 1 adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds.
AID1865087Displacement of [3H]DTG from sigma 2 receptor in rat liver membranes measured after 120 mins by scintillation counting method
AID1637893Displacement of [3H]-(+)-pentazocine from sigma1 receptor in guinea pig brain cortex membranes measured after 120 mins by scintillation counting analysis2019MedChemComm, Feb-01, Volume: 10, Issue:2
Synthesis and receptor binding of thiophene bioisosteres of potent GluN2B ligands with a benzo[7]annulene-scaffold.
AID502297Antagonist activity at wild type NR1/NR2A receptor expressed in Xenopus oocytes assessed as ratio of residual current induced by agonist in presence of compound to residual current induced by agonist alone at 10 uM by two-electrode voltage-clamp method2010Bioorganic & medicinal chemistry letters, Sep-15, Volume: 20, Issue:18
Identification of a novel NR2B-selective NMDA receptor antagonist using a virtual screening approach.
AID204312Inhibition of [3H]- ifenprodil binding against Sigma opioid receptor type 2 from rat brain1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
A series of 6- and 7-piperazinyl- and -piperidinylmethylbenzoxazinones with dopamine D4 antagonist activity: discovery of a potential atypical antipsychotic agent.
AID538759Displacement of [3H](+)-pentazocine from sigma1 receptor guinea pig brain after 180 mins scintillation counting2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Conformationally constrained NR2B selective NMDA receptor antagonists derived from ifenprodil: Synthesis and biological evaluation of tetrahydro-3-benzazepine-1,7-diols.
AID1174073Displacement of [3H](+)-pentazocine from sigma1 receptor in guinea pig brain membranes after 180 mins by scintillation counting method2014Bioorganic & medicinal chemistry, Dec-01, Volume: 22, Issue:23
Synthesis, GluN2B affinity and selectivity of benzo[7]annulen-7-amines.
AID709974Modulation of NMDA receptor GluN2B subunit in FVB mouse CA1 pyramidal neurons assessed as decrease in EPSC amplitude at holding potential of -60 mV at 10 uM measured at 5 mins by patch clamp electrophysiological assay in presence of Mg2+ free ACSF contain2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Synthesis and biological characterization of 3-substituted 1H-indoles as ligands of GluN2B-containing N-methyl-D-aspartate receptors. Part 2.
AID1876641Antagonist activity at GluN1/GluN2B NMDA receptor (unknown origin) transfected in HEK293 cells assessed as inhibition of glycine induced current response at 10 uM in presence of L-glutamate by patch-clamp method2022European journal of medicinal chemistry, Jan-05, Volume: 227Discovery of novel brain-penetrant GluN2B NMDAR antagonists via pharmacophore-merging strategy as anti-stroke therapeutic agents.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508591NCATS Rat Liver Microsome Stability Profiling2020Scientific reports, 11-26, Volume: 10, Issue:1
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1508612NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Highly predictive and interpretable models for PAMPA permeability.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1645871NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling in pH 5 buffer2022Bioorganic & medicinal chemistry, 02-15, Volume: 56Using in vitro ADME data for lead compound selection: An emphasis on PAMPA pH 5 permeability and oral bioavailability.
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID493017Wombat Data for BeliefDocking2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
2D QSAR modeling and preliminary database searching for dopamine transporter inhibitors using genetic algorithm variable selection of Molconn Z descriptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (671)

TimeframeStudies, This Drug (%)All Drugs %
pre-199034 (5.07)18.7374
1990's172 (25.63)18.2507
2000's229 (34.13)29.6817
2010's199 (29.66)24.3611
2020's37 (5.51)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.93

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.93 (24.57)
Research Supply Index6.55 (2.92)
Research Growth Index5.12 (4.65)
Search Engine Demand Index54.73 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.93)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials10 (1.46%)5.53%
Reviews21 (3.07%)6.00%
Case Studies5 (0.73%)4.05%
Observational0 (0.00%)0.25%
Other649 (94.74%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized Open Label Phase 2b/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease [NCT04382924]Phase 2/Phase 3168 participants (Actual)Interventional2020-08-05Completed
Ifenprodil Tartrate Treatment of Adolescents With Post-traumatic Stress Disorder: a Double-blind, Placebo-controlled Trial [NCT01896388]Phase 1/Phase 210 participants (Actual)Interventional2014-01-21Completed
An Open Label Study of the Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough [NCT04318704]Phase 220 participants (Actual)Interventional2020-07-29Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT04382924 (7) [back to overview]Rate of Mechanical Ventilation in IP Versus Control Group Patients
NCT04382924 (7) [back to overview]Rate of Mortality in IP Versus Control Group Patients
NCT04382924 (7) [back to overview]Time to Return to Room Pressure (SpO2 > 94%) on Room Air
NCT04382924 (7) [back to overview]Duration of Mechanical Ventilation (if Applicable) in IP Versus Control Group Patients
NCT04382924 (7) [back to overview]NEWS Assessed Days 3, 5, 8 ,11 Daily While Hospitalized and on Days 15 and 29 in IP Versus Control Group Patients
NCT04382924 (7) [back to overview]Patient Clinical Status (on the WHO 7-point Ordinal Scale) at Day 15 in IP Versus SOC Control Group Patients:
NCT04382924 (7) [back to overview]Status on an Ordinal Scale Assessed Daily While Hospitalized and on Days 15 and 28 in IP Versus Control Group Patients

Rate of Mechanical Ventilation in IP Versus Control Group Patients

Rate of mechanical ventilation in 20 and 40 mg TID NP-120 versus control group (NCT04382924)
Timeframe: Up to Day 28

InterventionParticipants (Count of Participants)
Treatment Arm A5
Treatment Arm B2
Control Arm4

[back to top]

Rate of Mortality in IP Versus Control Group Patients

Rate of Overall Mortality in 20, 40 mg TID groups versus control group (NCT04382924)
Timeframe: Up to Day 29

InterventionParticipants (Count of Participants)
Treatment Arm A2
Treatment Arm B5
Control Arm4

[back to top]

Time to Return to Room Pressure (SpO2 > 94%) on Room Air

"Time to return to room pressure (SpO2 > 94%) on room air in patients in 20, 40 mg TID NP-120 groups versus control group with 94% blood oxygen levels at enrolment~Time-to-event endpoints with competing risk were analysed for each dosing group using the Cumulative Incidence Function-CIF (KM) graphical display. Data represents the time (in Days) it took for all participants in the group to return to room pressure air (e.g. the time when the CIF curve hit 100%)." (NCT04382924)
Timeframe: Up to Day 29

InterventionDays (Number)
Treatment Arm A4
Treatment Arm B5
Control Arm9

[back to top]

Duration of Mechanical Ventilation (if Applicable) in IP Versus Control Group Patients

Duration of mechanical ventilation in 20 and 40 mg TID subjects versus control who experience mechanical ventilation (NCT04382924)
Timeframe: Up to day 28

,,
Interventionparticipants (Number)
< 6 hours>= 12 hours but < 24 hours>= 24 hours but <72 hours>=72 hours but <120 hours>= 120 hoursOngoing at time of EOS (>= 24 hours but <72 hours
Control Arm000121
Treatment Arm A001031
Treatment Arm B100100

[back to top]

NEWS Assessed Days 3, 5, 8 ,11 Daily While Hospitalized and on Days 15 and 29 in IP Versus Control Group Patients

"National Early Warning Score assessed between baseline and Day 29 on subjects in 20, 40 mg TID NP-120 arms versus control group~The National Early Warning Score (NEWS) scale is a composite of 7 physiological parameters: Respiration Rate (per minute),Oxygen Saturations (%), Any Supplemental Oxygen, Temperature (°C), Systolic BP (mmHg), Heart Rate (per minute), Level of Consciousness. The aggregate results from all 7 physiological parameters are used to obtain the NEW Score., ranging from 0 - 20. Higher values reflect a worse outcome." (NCT04382924)
Timeframe: Days 3, 5, 8, 11, 25, 29

,,
Interventionscores on a scale (Mean)
BaselineDay 3Day 5Day 8Day 11Day 15Day 29
Control Arm4.54.43.73.03.21.81.3
Treatment Arm A4.74.23.83.53.02.41.1
Treatment Arm B4.53.73.33.13.01.81.4

[back to top]

Patient Clinical Status (on the WHO 7-point Ordinal Scale) at Day 15 in IP Versus SOC Control Group Patients:

"Not hospitalized, no limitations on activities~Not hospitalized, limitation on activities~Hospitalized, not requiring supplemental oxygen~Hospitalized, requiring supplemental oxygen~Hospitalized, on non-invasive ventilation or high flow oxygen devices~Hospitalized, on invasive mechanical ventilation or ECMO~Death" (NCT04382924)
Timeframe: Day 15

,,
InterventionParticipants (Count of Participants)
1. Not hospitalized no limitations on activities2. Not hospitalized but limitations on activities3. Hospitalized not requiring supplemental O24. Hospitalized and requires supplemental O25. Hospitalized and on non-invasive ventilation or high flow O26. Hospitalized and on mechanical ventilation or ECMO7. Death
Control Arm182167122
Treatment Arm A1071313120
Treatment Arm B99138113

[back to top]

Status on an Ordinal Scale Assessed Daily While Hospitalized and on Days 15 and 28 in IP Versus Control Group Patients

"WHO status of subjects at timepoints from baseline to day 28~Not hospitalized, no limitations on activities~Not hospitalized, limitation on activities~Hospitalized, not requiring supplemental oxygen~Hospitalized, requiring supplemental oxygen~Hospitalized, on non-invasive ventilation or high flow oxygen devices~Hospitalized, on invasive mechanical ventilation or ECMO~Death" (NCT04382924)
Timeframe: Days 1 through 28

,,
Interventionscores on a scale (Mean)
BaselineDay 3Day 5Day 8Day 11Day 15Day 28
Control Arm4.254.294.184.043.972.961.73
Treatment Arm A4.234.224.123.893.872.871.59
Treatment Arm B4.254.224.144.024.092.951.80

[back to top]